EUVIMEDEUVIMED entdecken
Crossref

Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy

Maike Scherf-Clavel iD, Anna Linda Leutritz, Andrea Gehrmann, Stefan Unterecker, Sebastian Walther, Sarah Kittel-Schneider

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Maike Scherf-Clavel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Amitriptyline, Models, Biological, Antidepressive Agents, Tricyclic, Pregnancy Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Interdisciplinary Center for Clinical Research, Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pharmacotherapy of maternal peripartum depression is an increasing challenge. Amitriptyline (AMI) is the most often used tricyclic antidepressant during pregnancy, but knowledge on pharmacokinetics in this special phase is lacking. Physiologically based pharmacokinetic (PBPK) modelling is a powerful tool to better understand pregnancy‐induced pharmacokinetic changes of medication. We aimed to improve the knowledge about AMI pharmacokinetics during pregnancy using PBPK modelling. Consequently, we aimed to add new information for an effective and safe pharmacotherapy in pregnant women.

Methods

A PBPK model, including AMI, but also its active metabolite nortriptyline (NOR), was developed to investigate pregnancy‐induced pharmacokinetic changes after AMI administration. The predicted drug exposure was compared to observed concentrations in pregnant patients in clinical routine. The PBPK model was set up using PK‐Sim Version 11.

Results

Serum concentration profiles were described successfully. During pregnancy, active moiety serum concentration of AMI (AMI + NOR) did not change; however, AMI concentration increased, whereas NOR concentration decreased.

Conclusions

With this model, we added valuable information on AMI pharmacokinetics during pregnancy (increased AMI concentration, decreased NOR concentration). For clinical practice the treating physician should be aware that despite active moiety serum concentration comparable to before pregnancy, tolerability may be affected due to increased AMI serum concentrations and as consequence increased anticholinergic effects. To keep the risk of therapy discontinuation during pregnancy low, we suggest performing therapeutic drug monitoring, especially to check the AMI serum concentration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmitriptylineModels, BiologicalAntidepressive Agents, TricyclicPregnancy ComplicationsFemaleHumansPregnancyAdultNortriptylineYoung Adult

Stichwörter der Autor:innen

PBPK‐modellingamitriptylineperipartal depressionpharmacokinetics

Substanzen

AmitriptylineAntidepressive Agents, TricyclicNortriptyline

Autor:innen und Institutionen

  • Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany.
  • Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Social Foundation Bamberg, Teaching Hospital of the University of Erlangen, Germany.
  • Department of Psychiatry and Neurobehavioural Science, University College Cork, Cork, Ireland.
  • APC Microbiome, University College Cork, Cork, Ireland.

ORCID-Profile: Maike Scherf-Clavel

Förderung

  • Interdisciplinary Center for Clinical Research
  • Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg

Zitieren

APA

Scherf-Clavel, M., Leutritz, A. L., Gehrmann, A., Unterecker, S., Walther, S., & Kittel-Schneider, S. (2025). Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70084

Vancouver

Scherf-Clavel M, Leutritz AL, Gehrmann A, Unterecker S, Walther S, Kittel-Schneider S. Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70084

BibTeX
@article{ScherfClavel2025,
  author = {Scherf-Clavel, Maike and Leutritz, Anna Linda and Gehrmann, Andrea and Unterecker, Stefan and Walther, Sebastian and Kittel-Schneider, Sarah},
  title = {Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70084}
}
Kostenlos starten →